drugset / Trial / NCT01597388

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

NCT01597388

Phase 1 Completed 99 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant

Timeline

Start
2012-05-08
Primary completion
2016-08-04
Completion
2026-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Vistusertib Small molecule Oral
Background Fulvestrant Small molecule Intramuscular

Indications